Candel Therapeutics, Inc. (NASDAQ:CADL) CTO Sells $103,404.84 in Stock

Candel Therapeutics, Inc. (NASDAQ:CADL) CTO Seshu Tyagarajan sold 14,322 shares of the business’s stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $7.22, for a total transaction of $103,404.84. Following the sale, the chief technology officer now directly owns 96,790 shares in the company, valued at $698,823.80. This trade represents a 12.89 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Seshu Tyagarajan also recently made the following trade(s):

• On Friday, November 29th, Seshu Tyagarajan sold 20,392 shares of Candel Therapeutics stock. The shares were sold at an average price of $4.56, for a total value of $92,987.52.

Candel Therapeutics Trading Down 13.4 %

NASDAQ CADL opened at $6.66 on Monday. The firm has a market capitalization of $216.32 million, a P/E ratio of -3.85 and a beta of -1.20. The firm’s fifty day moving average price is $6.61 and its two-hundred day moving average price is $6.28. Candel Therapeutics, Inc. has a 1 year low of $1.16 and a 1 year high of $14.60.

Institutional Investors Weigh In On Candel Therapeutics

Hedge funds have recently bought and sold shares of the company. Bank of New York Mellon Corp acquired a new position in Candel Therapeutics during the second quarter worth approximately $338,000. Geode Capital Management LLC increased its holdings in shares of Candel Therapeutics by 12.8% during the 3rd quarter. Geode Capital Management LLC now owns 448,997 shares of the company’s stock worth $3,112,000 after acquiring an additional 51,111 shares during the last quarter. HB Wealth Management LLC increased its holdings in shares of Candel Therapeutics by 54.1% during the 4th quarter. HB Wealth Management LLC now owns 87,300 shares of the company’s stock worth $696,000 after acquiring an additional 30,642 shares during the last quarter. Cubist Systematic Strategies LLC bought a new stake in Candel Therapeutics in the 2nd quarter valued at $162,000. Finally, Rhumbline Advisers acquired a new stake in Candel Therapeutics during the 2nd quarter valued at $143,000. 13.93% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and issued a $19.00 price target (up from $11.00) on shares of Candel Therapeutics in a research note on Wednesday, December 18th.

Candel Therapeutics Company Profile

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.